Case report:

Xiao Ma, Juping Chen, Junqiao Cheng, Jingbo Wang

Abstract readCase Reports

In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiao MaPreventive Care Department, Jinhua Maternity and Child Health Care Hospital, Jinhua, Zhejiang, China.

Juping ChenJinhua Maternity and Child Health Care Hospital, Jinhua, Zhejiang, China.

Junqiao ChengPreventive Care Department, Jinhua Maternity and Child Health Care Hospital, Jinhua, Zhejiang, China.

Jingbo WangPreventive Care Department, Jinhua Maternity and Child Health Care Hospital, Jinhua, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disseminated Bacille Calmette-Guérin (BCG) disease is a rare adverse reaction to BCG vaccination. We report a neonate presenting with a progressive left axillary mass 3 months post-vaccination. High-throughput sequencing confirmed Mycobacterium bovis (BCG strain) infection. Genetic testing confirmed inborn errors of immunity (IEI) caused by interleukin (IL) 12 receptor β1 deficiency. An expert panel diagnosed BCG disease (acute hematogenous disseminated BCG disease and axillary lymph node involvement) due to the immunodeficiency. After about 28 months of anti-BCG combination therapy with interferon-gamma (IFN-γ), the infection was successfully controlled. The patient continues to receive maintenance therapy with only interferon-gamma (IFN-γ). The study explores the optimal timing and target populations for BCG vaccination in high TB burden countries to minimize severe adverse effects.

Indexed as

BCG VaccineImmunologic Deficiency SyndromesMycobacterium bovisReceptors, Interleukin-12TuberculosisHumansInfantInfant, NewbornInterferon-gammaMaleMutationBCG VaccineIL12RB1 protein, humanInterferon-gammaReceptors, Interleukin-12Bacille Calmette-Guérin (BCG) vaccinedisseminated BCG diseaseIL12RB1 mutationimmunologymendelian susceptibility to mycobacterial disease

Identifiers

PMID41668770

DOI10.3389/fimmu.2025.1728612

PMCPMC12884637

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.